- Medicenna Therapeutics Corp MDNA11 Clinical Update Call TranscriptAug 09, 2023
- Medicenna Therapeutics Corp at Bloom Burton & Co Healthcare Investor Conference TranscriptApr 25, 2023
- Medicenna Therapeutics Corp at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Medicenna Therapeutics Corp at Guggenheim Healthcare Talks Oncology Day TranscriptFeb 09, 2023
- Q3 2023 Medicenna Therapeutics Corp Earnings Call TranscriptFeb 07, 2023C$1 (-0.99%)Earnings
- Q2 2023 Medicenna Therapeutics Corp Earnings Call TranscriptNov 04, 2022C$0.88 (-4.35%)Earnings
- Medicenna Therapeutics Corp Annual Shareholders Meeting TranscriptSep 21, 2022
- Q1 2023 Medicenna Therapeutics Corp Earnings Call TranscriptAug 15, 2022C$1.27 (-6.62%)Earnings
- Q4 2022 Medicenna Therapeutics Corp Earnings Call TranscriptJun 22, 2022C$1.27 (+14.41%)Earnings
- Medicenna Therapeutics Corp at Bloom Burton & Co. Healthcare Investor Conference TranscriptMay 02, 2022
- Q3 2022 Medicenna Therapeutics Corp Earnings Call TranscriptFeb 09, 2022C$2.31 (-2.53%)Earnings
- Q2 2022 Medicenna Therapeutics Corp Earnings Call TranscriptNov 12, 2021C$2.56Earnings
- Medicenna Therapeutics Corp Annual Shareholders Meeting TranscriptSep 23, 2021
- Medicenna Therapeutics Corp at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) TranscriptSep 20, 2021
- Q1 2022 Medicenna Therapeutics Corp Earnings Call TranscriptAug 13, 2021C$2.61 (-4.74%)Earnings
- Medicenna Therapeutics Corp MDNA11 Program Update Call TranscriptJul 27, 2021
- Q4 2021 Medicenna Therapeutics Corp Earnings Call TranscriptMay 28, 2021C$4.7 (-0.42%)Earnings
- Medicenna Therapeutics Corp at Cowen Healthcare Conference (Virtual) TranscriptMar 02, 2021
- Medicenna Therapeutics Corp. - Special Call TranscriptDec 11, 2020
- Medicenna Therapeutics Corp. - Special Call TranscriptMar 25, 2020
- Medicenna Therapeutics Corp to Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results TranscriptNov 25, 2019
Medicenna Therapeutics Corp at Cowen Healthcare Conference (Virtual) Transcript
Hello. Welcome to our fireside chat with Medicenna Therapeutics. I have with me President and CEO, Fahar Merchant. Medicenna is developing Superkines as immunotherapy for cancer. Their lead program is in GBM, and then IL-2 program is another key focus.
We'll start with an overview of the company followed by Q&A. So feel free to put any questions you have on the online portal, and we'll get to them at the end of the presentation. And with that, I will hand it over to Fahar.
Well, thank you very much. I'm glad that you could make it to this presentation and fireside chat. Just to let you know, I'll be making forward-looking statements, so I encourage you to look at our regulatory filings for these risk factors, et cetera.
So the company is a Canadian company. We are based out of Toronto but listed both on NASDAQ as well as TSX. The company's focus, really, as was mentioned,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)